Contact Us
Global T Cell Specific Surface Glycoprotein CD28 Market Report 2025

T Cell Specific Surface Glycoprotein CD28 Global Market Report 2025 - By Type (FPT 155, FR 104, Lulizumab Pegol, Other Types), By Technology (Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry), By Distribution Channel (Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers), By Application (Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research), By End-User (Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories) - Market Size, Trends, And Global Forecast 2025-2034

T Cell Specific Surface Glycoprotein CD28 Global Market Report 2025

Report Price : $4490.00 | Pages : 250 | Published : September 2025 | Delivery Time: 2-3 business days Info icon | Format : pdf icon

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

T Cell Specific Surface Glycoprotein CD28 Market Overview

• T Cell Specific Surface Glycoprotein CD28 market size has reached to $1.47 billion in 2024

• Expected to grow to $2.35 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%

• Growth Driver: Growing Emphasis On Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomic Technologies

• Market Trend: Breakthrough CD28 Approach Aims To Minimize Off-Target Toxicity In Cancer Treatment

North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under T Cell Specific Surface Glycoprotein CD28 Market?

T cell-specific surface glycoprotein CD28 is a co-stimulatory receptor expressed on the surface of most T cells. It binds to B7 molecules (CD80/CD86) on antigen-presenting cells, delivering essential secondary signals for T cell activation, proliferation, and survival. Its primary purpose is to enhance immune responses by promoting cytokine production and preventing T cell anergy.

The main types of T cell specific surface glycoprotein CD28 include FPT155, FR104, Lulizumab Pegol, and others. FPT155 is an investigational therapeutic protein that functions as an immune co-stimulatory fusion protein, targeting CD80 to activate T cells and enhance anti-tumor immune responses. These products utilize various technologies such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), western blotting, and immunohistochemistry, and are distributed through various channels including direct sales, distributors, e-commerce, retail pharmacies, and wholesalers. They are used in diverse applications such as immunology research, cancer research, autoimmune diseases, infectious diseases, and stem cell research, with key end users including hospitals, research laboratories, academic institutions, pharmaceutical companies, and diagnostic laboratories.

T Cell Specific Surface Glycoprotein CD28 Market Size and growth rate 2025 to 2029: Graph

What Is The T Cell Specific Surface Glycoprotein CD28 Market Size 2025 And Growth Rate?

The T cell-specific surface glycoprotein CD28 market size has grown rapidly in recent years. It will grow from $1.47 billion in 2024 to $1.62 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing research in immunotherapy, rising prevalence of cancer, rise in autoimmune disease cases, increasing clinical trials, and rising adoption of monoclonal antibodies.

What Is The T Cell Specific Surface Glycoprotein CD28 Market Growth Forecast?

The T cell-specific surface glycoprotein CD28 market size is expected to see strong growth in the next few years. It will grow to $2.35 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, growing focus on T-cell-based therapies, rising awareness about immuno-oncology, an increasing pipeline of targeted therapies, growing investments by pharmaceutical companies, and expanding applications in chronic diseases. Major trends in the forecast period include advancement in cell engineering technologies, advanced development of bispecific antibodies, innovation in targeted immunotherapies, integration of AI in drug discovery, and advancement in manufacturing of biologics.

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The T Cell Specific Surface Glycoprotein CD28 Market Segmented?

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

What Is Driving The T Cell Specific Surface Glycoprotein CD28 Market? Growing Emphasis On Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomic Technologies

The growing emphasis on personalized medicine is expected to propel the growth of the T cell-specific surface glycoprotein CD28 market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable precise identification of genetic variations and tailored treatments for individuals. T cell-specific surface glycoprotein CD28 supports personalized medicine by enabling targeted immune modulation, making therapies more precise and effective. It enhances treatment outcomes by promoting optimal T cell activation, improving patient-specific immune responses. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, an increase from 12 approved in 2022. Therefore, the growing emphasis on personalized medicine is driving the growth of the T cell-specific surface glycoprotein CD28 market.

Who Are The Major Players In The Global T Cell Specific Surface Glycoprotein CD28 Market?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

What Are The Key Trends Of The Global T Cell Specific Surface Glycoprotein CD28 Market? Breakthrough CD28 Approach Aims To Minimize Off-Target Toxicity In Cancer Treatment

Major companies operating in the T cell-specific surface glycoprotein CD28 market are focusing on developing innovative products, such as the combination immunotherapies, to enhance T cell activation, anti-tumor efficacy, and patient treatment outcomes. Combination immunotherapies are treatments that combine multiple immune-based approaches to boost the body’s ability to fight disease. For instance, in February 2025, Rondo Therapeutics Inc., a US-based biopharmaceutical company, revealed preclinical data on RNDO 564, a novel CD28 Nectin 4 costimulatory bispecific antibody for advanced bladder cancer. It is engineered to selectively activate CD28 on T cells upon binding to Nectin-4-expressing tumor cells, enhancing T-cell-mediated tumor killing while minimizing off-target toxicity. The data demonstrated potent anti-tumor activity in preclinical models, supporting further development as a potential therapy for patients with metastatic urothelial carcinoma.

What Are Latest Mergers And Acquisitions In The T Cell Specific Surface Glycoprotein CD28 Market? Eli Lilly Joins Rondo To Advance CD28-Driven Cancer Treatments

In December 2024, Rondo Therapeutics Inc., a US-based biopharmaceutical company, partnered with Eli Lilly and Company to develop new CD28 bispecific antibodies for solid tumors. This partnership aims to enhance T cell co-stimulation and improve anti-tumor immune responses while minimizing immune-related toxicity, thereby advancing next-generation immuno-oncology therapies. Eli Lilly and Company is a US-based biopharmaceutical company developing CD28-targeted immuno-oncology therapies.

What Is The Regional Outlook For The Global T Cell Specific Surface Glycoprotein CD28 Market?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the T Cell Specific Surface Glycoprotein CD28 Market?

The T cell-specific surface glycoprotein CD28 market consists of revenues earned by entities by providing services such as drug discovery, antibody development, cell signaling assays, immuno-oncology research, diagnostic testing, and clinical trial support targeting CD28 pathways. The market value includes the value of related goods sold by the service provider or included within the service offering. The T cell-specific surface glycoprotein CD28 market also includes sales of CD28 fusion proteins, CD28 ligands, flow cytometry reagents, and diagnostic assays and kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the T Cell Specific Surface Glycoprotein CD28 Industry?

The t cell specific surface glycoprotein cd28 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the t cell specific surface glycoprotein cd28 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author: Abdul Wasay

T Cell Specific Surface Glycoprotein CD28 Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $1.62 billion
Revenue Forecast In 2034 $2.35 billion
Growth Rate CAGR of 9.8% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered Type, Technology, Distribution Channel, Application, End-User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. T Cell Specific Surface Glycoprotein CD28 Market Characteristics

    3. T Cell Specific Surface Glycoprotein CD28 Market Trends And Strategies

    4. T Cell Specific Surface Glycoprotein CD28 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

    4.1. Supply Chain Impact from Tariff War & Trade Protectionism

    5. Global T Cell Specific Surface Glycoprotein CD28 Growth Analysis And Strategic Analysis Framework

    5.1. Global T Cell Specific Surface Glycoprotein CD28 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global T Cell Specific Surface Glycoprotein CD28 Market Growth Rate Analysis

    5.4. Global T Cell Specific Surface Glycoprotein CD28 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global T Cell Specific Surface Glycoprotein CD28 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global T Cell Specific Surface Glycoprotein CD28 Total Addressable Market (TAM)

    6. T Cell Specific Surface Glycoprotein CD28 Market Segmentation

    6.1. Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    FPT 155

    FR 104

    Lulizumab Pegol

    Other Types

    6.2. Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Flow Cytometry

    Enzyme Linked Immunosorbent Assay (ELISA)

    Polymerase Chain Reaction (PCR)

    Weste Blotting

    Immunohistochemistry

    6.3. Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Direct Sales

    Distributors

    Ecommerce

    Retail Pharmacies

    Wholesalers

    6.4. Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Immunology Research

    Cancer Research

    Autoimmune Diseases

    Infectious Diseases

    Stem Cell Research

    6.5. Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By EndUser, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Research Laboratories

    Academic Institutions

    Pharmaceutical Companies

    Diagnostic Laboratories

    6.6. Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of FPT 155, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Preclinical Studies

    Clinical Trials

    Oncology Applications

    Licensing And Partnerships

    6.7. Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of FR 104, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Autoimmune Disease Applications

    Rheumatoid Arthritis Trials

    Transplant Rejection Studies

    Research Collaborations

    6.8. Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of Lulizumab Pegol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Systemic Lupus Erythematosus (SLE) Studies

    Immunomodulation Research

    Biopharmaceutical Development

    Monoclonal Antibody Engineering

    6.9. Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Novel CD28 Inhibitors

    Combination Therapies

    Biosimilars And Biobetters

    Emerging Research Compounds

    7. T Cell Specific Surface Glycoprotein CD28 Market Regional And Country Analysis

    7.1. Global T Cell Specific Surface Glycoprotein CD28 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global T Cell Specific Surface Glycoprotein CD28 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Market

    8.1. Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China T Cell Specific Surface Glycoprotein CD28 Market

    9.1. China T Cell Specific Surface Glycoprotein CD28 Market Overview

    9.2. China T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India T Cell Specific Surface Glycoprotein CD28 Market

    10.1. India T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan T Cell Specific Surface Glycoprotein CD28 Market

    11.1. Japan T Cell Specific Surface Glycoprotein CD28 Market Overview

    11.2. Japan T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia T Cell Specific Surface Glycoprotein CD28 Market

    12.1. Australia T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia T Cell Specific Surface Glycoprotein CD28 Market

    13.1. Indonesia T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea T Cell Specific Surface Glycoprotein CD28 Market

    14.1. South Korea T Cell Specific Surface Glycoprotein CD28 Market Overview

    14.2. South Korea T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe T Cell Specific Surface Glycoprotein CD28 Market

    15.1. Western Europe T Cell Specific Surface Glycoprotein CD28 Market Overview

    15.2. Western Europe T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK T Cell Specific Surface Glycoprotein CD28 Market

    16.1. UK T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany T Cell Specific Surface Glycoprotein CD28 Market

    17.1. Germany T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France T Cell Specific Surface Glycoprotein CD28 Market

    18.1. France T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy T Cell Specific Surface Glycoprotein CD28 Market

    19.1. Italy T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain T Cell Specific Surface Glycoprotein CD28 Market

    20.1. Spain T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe T Cell Specific Surface Glycoprotein CD28 Market

    21.1. Eastern Europe T Cell Specific Surface Glycoprotein CD28 Market Overview

    21.2. Eastern Europe T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia T Cell Specific Surface Glycoprotein CD28 Market

    22.1. Russia T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America T Cell Specific Surface Glycoprotein CD28 Market

    23.1. North America T Cell Specific Surface Glycoprotein CD28 Market Overview

    23.2. North America T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA T Cell Specific Surface Glycoprotein CD28 Market

    24.1. USA T Cell Specific Surface Glycoprotein CD28 Market Overview

    24.2. USA T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada T Cell Specific Surface Glycoprotein CD28 Market

    25.1. Canada T Cell Specific Surface Glycoprotein CD28 Market Overview

    25.2. Canada T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America T Cell Specific Surface Glycoprotein CD28 Market

    26.1. South America T Cell Specific Surface Glycoprotein CD28 Market Overview

    26.2. South America T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil T Cell Specific Surface Glycoprotein CD28 Market

    27.1. Brazil T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East T Cell Specific Surface Glycoprotein CD28 Market

    28.1. Middle East T Cell Specific Surface Glycoprotein CD28 Market Overview

    28.2. Middle East T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa T Cell Specific Surface Glycoprotein CD28 Market

    29.1. Africa T Cell Specific Surface Glycoprotein CD28 Market Overview

    29.2. Africa T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. T Cell Specific Surface Glycoprotein CD28 Market Competitive Landscape And Company Profiles

    30.1. T Cell Specific Surface Glycoprotein CD28 Market Competitive Landscape

    30.2. T Cell Specific Surface Glycoprotein CD28 Market Company Profiles

    30.2.1. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

    31. T Cell Specific Surface Glycoprotein CD28 Market Other Major And Innovative Companies

    31.1. Becton Dickinson and Company

    31.2. Regeneron Pharmaceuticals Inc.

    31.3. Bio-Techne Corporation

    31.4. STEMCELL Technologies Inc.

    31.5. Miltenyi Biotec B.V. & Co. KG

    31.6. Sino Biological Inc.

    31.7. Xencor Inc.

    31.8. ACROBiosystems Co. Ltd.

    31.9. Fate Therapeutics Inc.

    31.10. Medigene AG

    31.11. Alpine Immune Sciences Inc.

    31.12. Adaptimmune Therapeutics plc

    31.13. OSE Immunotherapeutics SA

    31.14. Creative Biolabs Inc.

    31.15. Rondo Therapeutics Inc.

    32. Global T Cell Specific Surface Glycoprotein CD28 Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The T Cell Specific Surface Glycoprotein CD28 Market

    34. Recent Developments In The T Cell Specific Surface Glycoprotein CD28 Market

    35. T Cell Specific Surface Glycoprotein CD28 Market High Potential Countries, Segments and Strategies

    35.1 T Cell Specific Surface Glycoprotein CD28 Market In 2029 - Countries Offering Most New Opportunities

    35.2 T Cell Specific Surface Glycoprotein CD28 Market In 2029 - Segments Offering Most New Opportunities

    35.3 T Cell Specific Surface Glycoprotein CD28 Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By EndUser, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of FPT 155, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of FR 104, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of Lulizumab Pegol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global T Cell Specific Surface Glycoprotein CD28 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global T Cell Specific Surface Glycoprotein CD28 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Gilead Sciences Inc. Financial Performance
  • Table 81: Johnson & Johnson Financial Performance
  • Table 82: Novartis AG Financial Performance
  • Table 83: Bristol-Myers Squibb Company Financial Performance
  • Table 84: Takeda Pharmaceutical Company Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By EndUser, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of FPT 155, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of FR 104, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of Lulizumab Pegol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global T Cell Specific Surface Glycoprotein CD28 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global T Cell Specific Surface Glycoprotein CD28 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global T Cell Specific Surface Glycoprotein CD28 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, T Cell Specific Surface Glycoprotein CD28 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Gilead Sciences Inc. Financial Performance
  • Figure 81: Johnson & Johnson Financial Performance
  • Figure 82: Novartis AG Financial Performance
  • Figure 83: Bristol-Myers Squibb Company Financial Performance
  • Figure 84: Takeda Pharmaceutical Company Limited Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the T Cell Specific Surface Glycoprotein CD28 market?

T cell-specific surface glycoprotein CD28 is a co-stimulatory receptor expressed on the surface of most T cells. It binds to B7 molecules (CD80/CD86) on antigen-presenting cells, delivering essential secondary signals for T cell activation, proliferation, and survival. Its primary purpose is to enhance immune responses by promoting cytokine production and preventing T cell anergy. For further insights on this market, request a sample here

How will the T Cell Specific Surface Glycoprotein CD28 market drivers and restraints affect the market dynamics? What forces will shape the T Cell Specific Surface Glycoprotein CD28 industry going forward?

The market major growth driver - Growing Emphasis On Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomic Technologies. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the T Cell Specific Surface Glycoprotein CD28 market?

The T cell-specific surface glycoprotein CD28 market size has grown rapidly in recent years. It will grow from $1.47 billion in 2024 to $1.62 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing research in immunotherapy, rising prevalence of cancer, rise in autoimmune disease cases, increasing clinical trials, and rising adoption of monoclonal antibodies. The T cell-specific surface glycoprotein CD28 market size is expected to see strong growth in the next few years. It will grow to $2.35 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, growing focus on T-cell-based therapies, rising awareness about immuno-oncology, an increasing pipeline of targeted therapies, growing investments by pharmaceutical companies, and expanding applications in chronic diseases. Major trends in the forecast period include advancement in cell engineering technologies, advanced development of bispecific antibodies, innovation in targeted immunotherapies, integration of AI in drug discovery, and advancement in manufacturing of biologics. For further insights on this market, request a sample here

How is the T Cell Specific Surface Glycoprotein CD28 market segmented?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented
1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types
2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry
3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers
4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research
5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories Subsegments:
1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships
2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations
3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering
4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds For further insights on this market,
request a sample here

Which region has the largest share of the T Cell Specific Surface Glycoprotein CD28 market? What are the other regions covered in the report?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the T Cell Specific Surface Glycoprotein CD28 market?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc. . For further insights on this market, request a sample here.

What are the key trends in the T Cell Specific Surface Glycoprotein CD28 market?

Major trends in this market include Breakthrough CD28 Approach Aims To Minimize Off-Target Toxicity In Cancer Treatment. For further insights on this market, request a sample here.

Back to top
Back to top